The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Primary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares the results from the primary analysis of the Phase III TRANSFORM study (NCT03575351) comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (autoSCT) as second-line treatment in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). After a median follow-up of 17.5 months, the event-free survival (EFS) was not reached in the liso-cel arm and was 2.4 months in the SOC arm. In addition, there were no serious adverse events and no new safety signals. Patients who crossed over to receive liso-cel after they did not achieve complete or partial response with SOC had a worse EFS than patients who were treated directly with liso-cel. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
TG Therapeutics: Consultancy, Research Funding; Genentech: Consultancy, Other: DMC, Research Funding; Novartis: Research Funding; Abbvie: Consultancy; AstraZeneca: Consultancy; BMS: Consultancy; Adaptive Technologies: Consultancy; ADC Therapeutics: Consultancy; Beigene: Consultancy; Impact Bio: Consultancy; SeaGen: Speakers Bureau; Celgene: Other: DMC.
